How to Calculate Covenant Headroom, Debt Capacity and an Equity Cure

Knowing what a covenant is gets you through the first thirty seconds of a leveraged finance interview. Being able to calculate covenant headroom, work out how much incremental debt a package permits, and size an equity cure under pressure is what gets you through the rest of it. This article walks through the full sequence on a single set of numbers, using the capital structure from the covenant analysis case on get-into-finance so you can practise the same calculation end to end afterwards.

The company we are testing

A German industrials issuer funds itself with a senior secured term loan and senior unsecured high yield notes. All figures are in EUR millions on a last-twelve-months basis.

The documentation contains two maintenance covenants in the term loan — Consolidated Net Leverage of no more than 3.50x and Interest Coverage of at least 3.00x, both tested quarterly — and two incurrence tests in the notes: a Fixed Charge Coverage Ratio of at least 2.00x pro forma before new debt, and a Consolidated Secured Net Leverage Ratio of no more than 3.00x pro forma before new secured debt. The restricted payments basket is 50% of cumulative Consolidated Net Income plus a €25.0m general basket.

Step 1: Build Consolidated EBITDA, not reported EBITDA

Every ratio in a credit agreement runs off a defined term, and that defined term is almost never the number the company reports to the market. Start here or everything downstream is wrong.

Consolidated EBITDA = Reported EBITDA + Permitted Non-Recurring Add-Backs + Permitted Run-Rate Cost Savings

Consolidated EBITDA = €180.0m + €12.0m + €8.0m = €200.0m

Now test the cap: 10% × €200.0m = €20.0m, comfortably above the €8.0m of claimed savings, so the full amount is permitted. Do this check explicitly. Interviewers include a cap precisely to see whether you notice it, and in real documentation the cap frequently binds — synergy add-back allowances of 20% to 25% of EBITDA with no realisation deadline are common in aggressive deals, and they are the mechanism by which several turns of phantom headroom get created.

The general principle is that every euro of permitted add-back lowers every leverage ratio and raises every coverage ratio at the same time. That leverage on the answer is why add-back definitions are among the most negotiated provisions in the entire document, and why any serious credit analyst rebuilds the number from reported figures before trusting it. The judgement about which items legitimately come out and which are being smuggled through is the same one tested in an EBITDA normalisation case, and it is worth being fluent in it before attempting covenant arithmetic. If you are shakier on the mechanics of getting to EBITDA in the first place, the bridge from net income up to EBITDA is the prerequisite.

Step 2: Test the leverage maintenance covenant

Total Debt = €450.0m + €250.0m = €700.0m

Net Debt = €700.0m − €60.0m = €640.0m

Consolidated Net Leverage Ratio = €640.0m / €200.0m = 3.20x

Against a 3.50x covenant, the issuer passes. But "passes" is a weak answer on its own. The follow-up is always about headroom, and there are two ways to express it that carry very different information.

Headroom as debt capacity. Maximum permitted net debt = 3.50 × €200.0m = €700.0m. Against actual net debt of €640.0m, that leaves €60.0m of room.

Headroom as an earnings cushion. The minimum Consolidated EBITDA that keeps the ratio at exactly 3.50x is €640.0m / 3.50 = €182.9m. Relative to €200.0m, that is a permitted decline of (€200.0m − €182.9m) / €200.0m = 8.6%.

The second framing is the one that matters, and stating it unprompted is a genuine differentiator. An 8.6% EBITDA cushion sounds comfortable in the abstract and is not: it sits well inside the range of an ordinary cyclical downturn for an industrials business. Under 10% is roughly the threshold at which lenders begin pre-negotiating amendments rather than waiting for the test date, and it is the number a rating agency or a distressed desk will quote when arguing about how close a structure sits to a restructuring conversation.

Step 3: Test the coverage maintenance covenant

Total Cash Interest Expense = (€450.0m × 4.0%) + (€250.0m × 6.0%) = €18.0m + €15.0m = €33.0m

Interest Coverage Ratio = €200.0m / €33.0m = 6.06x

Against a 3.00x covenant this passes with wide margin. Leverage binds long before coverage does, which is worth naming because it characterises the whole structure: this is the profile of a capital structure built when funding costs were low. Note what happens under a rate shock — if the term loan were floating and base rates rose 300 basis points, cash interest would climb to roughly €46.5m and coverage would drop to about 4.3x. Still passing, but the gap between the two tests would narrow substantially, and repeating that move a second time flips which covenant binds. This is exactly what happened across large parts of the leveraged loan market as rates rose, and being able to say so shows you understand covenants as live constraints rather than as static ratios on a page. The same sensitivity to coupon structure sits behind the relationship between yields, prices and duration on the instrument side.

Step 4: Solve the incurrence tests for maximum debt capacity

This is where most candidates lose points, in one of two ways: by testing incurrence covenants as though they ran quarterly, or by stopping at the first test that produces a number. Incurrence covenants are only tested when the issuer takes an action, and the permitted amount is always the minimum across every applicable test.

Assume the issuer wants to raise senior secured debt at a 7.0% coupon to fund an acquisition, with proceeds spent immediately so cash is unchanged and no acquired earnings are credited pro forma.

Test A — Fixed Charge Coverage Ratio. Where X is the new debt raised:

€200.0m / (€33.0m + 0.070 × X) ≥ 2.00

€33.0m + 0.070 × X ≤ €100.0m

0.070 × X ≤ €67.0m → X ≤ €957.1m

Test B — Consolidated Secured Net Leverage Ratio. Where S is the new secured debt:

(€450.0m + S − €60.0m) / €200.0m ≤ 3.00

€390.0m + S ≤ €600.0m → S ≤ €210.0m

The answer is €210.0m, and the reason the two tests diverge so dramatically is structural. The Fixed Charge Coverage Ratio is a flow test measuring earnings against annual cash cost, and when coupons are low relative to EBITDA it is easy to satisfy — which is why it rarely binds for a healthy issuer. The secured leverage test is a stock test measuring the entire secured claim against the entire earnings base, and it exists specifically to stop unsecured noteholders from being structurally subordinated by new secured borrowing that would rank ahead of them in a recovery.

One further nuance worth raising: if the issuer raised the money as unsecured rather than secured debt, the secured test would not apply at all, and capacity would jump toward the €957.1m the coverage test allows. The honest answer is that it would never get there — a total net leverage incurrence test, the rating agencies, and the clearing price the market would demand for that much new paper would all bind long before the documentation did. Distinguishing covenant capacity from market capacity is the kind of remark that reads as deal experience rather than textbook recall, and it connects directly to how debt capacity is sized in practice using leverage, covenants and free cash flow serviceability together.

Step 5: Size the restricted payments basket

Restricted payments cover cash leaving the credit group — dividends, buybacks, voluntary junior debt payments. The builder basket accumulates with earnings; the general basket is granted upfront.

Assume Consolidated Net Income since the issue date of €24.0m, €30.0m and €36.0m across three years, with €18.0m of restricted payments already made.

First check the condition: the builder basket is usable only if the Fixed Charge Coverage Ratio test is satisfied. At 6.06x against a 2.00x threshold, it is.

Cumulative Consolidated Net Income = €24.0m + €30.0m + €36.0m = €90.0m

Builder basket = 50% (0.50) × €90.0m = €45.0m

Available RP capacity = €45.0m + €25.0m − €18.0m = €52.0m

The design here is worth appreciating. Tying the basket to cumulative net income means the sponsor's ability to take cash out grows only as the business actually performs, which aligns extraction with results rather than granting a fixed allowance upfront. The starter basket exists so there is some day-one flexibility before income has accumulated.

In practice, €52.0m is far too small for a sponsor planning a meaningful return of capital, which is why most dividend recapitalisations are not funded out of the existing basket at all but out of new debt raised alongside the payment — meaning the ratio debt test and the restricted payments condition have to be satisfied pro forma for the enlarged structure simultaneously. When neither works, the remaining routes are a consent solicitation, a full refinancing of the notes, or a dividend at a holding company outside the restricted group funded with PIK paper.

Step 6: Size the equity cure in the downside case

Now stress it. Suppose Consolidated EBITDA comes in 20% below plan at the next test date, with net debt unchanged.

Downside Consolidated EBITDA = €200.0m × (1 − 0.20) = €160.0m

Consolidated Net Leverage Ratio = €640.0m / €160.0m = 4.00x against a 3.50x covenant — a breach.

This is a maintenance covenant, so the breach happens automatically. Nothing was incurred and no action was taken; earnings simply fell, and the passage of time did the rest. That is the entire practical difference between the two covenant types, and it is why the sponsor now needs a cure.

Mechanic A — EBITDA cure. The injection is deemed an addition to Consolidated EBITDA.

Minimum Consolidated EBITDA required = €640.0m / 3.50 = €182.9m

Cure amount = €182.9m − €160.0m = €22.9m

Mechanic B — debt paydown cure. The injection must be applied to reduce debt.

Maximum permitted net debt = 3.50 × €160.0m = €560.0m

Cure amount = €640.0m − €560.0m = €80.0m

The €57.1m gap is the whole negotiation. Because leverage is a ratio, curing through the denominator is more capital-efficient than curing through the numerator by exactly the covenant multiple — 3.50x here, which is not a coincidence but a mathematical identity. Sponsors push for the EBITDA cure and for cured amounts to roll forward into subsequent test periods; lenders push for debt paydown, for caps on frequency, and for no over-curing beyond the minimum needed to pass. Whether a document permits an EBITDA cure is one of the fastest available reads on how borrower-friendly the package is.

Note also the assumption that matters: cure proceeds added to EBITDA are not simultaneously netted against debt. Doing both would double count the injection and understate the required cure, and it is a common slip under time pressure.

The six numbers, and what each one is for

• Consolidated EBITDA €200.0m — the base every other calculation runs off
• Net leverage 3.20x vs. 3.50x — pass, with €60.0m of debt headroom or an 8.6% earnings cushion
• Interest coverage 6.06x vs. 3.00x — pass, with leverage clearly the binding maintenance test
• Incremental secured debt capacity €210.0m — the secured leverage test binds ahead of the €957.1m the coverage test allows
• Restricted payments capacity €52.0m — the ceiling on a sponsor dividend without new financing
• Equity cure €22.9m as an EBITDA cure vs. €80.0m as debt paydown

These are not academic outputs. The €210.0m tells corporate development how large an acquisition it can debt-fund without a consent process. The €52.0m sets the sponsor's dividend ceiling. The 8.6% cushion is what a credit committee quotes when deciding whether to pre-emptively renegotiate. And the €22.9m is what a sponsor writes a cheque for if the downside materialises — assuming it still believes the equity is worth defending.

Five mistakes that cost candidates the question

Testing incurrence covenants quarterly. If the Fixed Charge Coverage Ratio falls below 2.00x and the company has not incurred debt or paid a dividend, nothing has happened. No breach, no default, no lender remedy — only certain doors temporarily closed. Saying "the company is in default" reveals you have never read an indenture.

Stopping at the first incurrence test. The €957.1m from the coverage test is irrelevant once the secured leverage test caps the raise at €210.0m. Capacity is the minimum across all applicable tests plus any available baskets, and interviewers construct these questions so the obvious test is not the binding one.

Using reported instead of Consolidated EBITDA. Ignoring permitted add-backs understates headroom by a full turn or more, and the covenant is calculated off the defined term regardless of what the company reports externally.

Sizing an equity cure by debt reduction when an EBITDA cure is available. Reaching for €80.0m when the document permits €22.9m is a three-and-a-half-times error, and it signals that you have not internalised why the mechanic matters.

Double counting the cure. Adding the injection to EBITDA while also netting it against debt inflates the effect and understates the required amount.

Practising the sequence

Covenant questions are common in leveraged finance, debt capital markets, restructuring and private equity interviews, and they reward drilling because the sequence is always the same: build the defined EBITDA, test the maintenance covenants, solve each incurrence test separately and take the minimum, size the baskets, then stress it and cure. Six steps, and the arithmetic is not hard once the order is automatic.

The full worked version of everything above, with the formula boxes, the follow-up questions on unsecured incurrence and over-cure mechanics, and the common-mistakes list, is available as the Covenant Analysis: IG vs. HY case. It sits naturally alongside the high yield versus investment grade comparison for the conceptual grounding, the LBO debt schedule for how interest, amortisation and cash sweeps actually build up over the life of a structure, and the distressed LBO and debt-for-equity swap case for what happens when the cures run out and the creditor hierarchy has to be worked through in earnest.